Journal of Endocrinological Investigation

, Volume 28, Issue 3, pp 79–88 | Cite as

The role of luteinizing hormone activity in controlled ovarian stimulation

  • N. Angelopoulos
  • A. Goula
  • G. Tolis
Review Article


The role of LH in the natural menstrual cycle is undisputed. The active participation of LH in both steroidogenesis and ovulation is well established, but its potential effect on oocyte maturation in the issue of assisted reproduction protocols remains a topic of debate. Although several studies have added to our understanding of the specific actions of androgens in human follicular development, some discrepancies persist regarding their role in oocyte atresia. Clinical situations, where LH is either decreased or absent (e.g. in women with hypogonadotrophic hypogonadism or LH-receptor gene mutations), provide important data supporting the necessity for a minimal amount of LH to evoke ovulation. Recent use of GnRH antagonists, which results in profound suppression of LH concentration, in combination with the pharmacological production of recombinant gonadotrophins, has attracted the attention of investigators. Identification of sub-fertilized women, in whom LH administration could be beneficial and should be indicated, is arousing ever more interest. Based on the available data in the literature, the aims of this review are to assess the role of both endogenous and exogenous LH activity in stimulated cycles, and to evaluate the effects of recombinant human LH supplementation on the ovarian hormonal milieu and on the main outcomes of controlled stimulated cycles.


Luteinizing hormone ovulation recombinant gonadotrophins androgens estrogens 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Human Reprod 1986, 1: 81–7.Google Scholar
  2. 2.
    Ryan KJ, Petro Z, Kaiser J. Steroid formation by isolated and recombined ovarian granulosa and thecal cells. J Clin Endocrinol Metab 1968, 28: 355–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Leymarie P, Savard K. Steroid hormone formation in the human ovary. VI. Evidence for two pathways of synthesis of androgens in the stromal compartment. J Clin Endocrinol Metab 1968, 28: 1547–54.PubMedCrossRefGoogle Scholar
  4. 4.
    Somma M, Sandor T, Lanthier A. Site of origin of androgenic and estrogenic steroids in the normal human ovary. J Clin Endocrinol Metab 1969, 29: 457–66.PubMedCrossRefGoogle Scholar
  5. 5.
    Tsafriri A, Channing CP. An inhibitory influence of granulosa cells and follicular fluid upon porcine oocyte meiosis in vitro. Endocrinology 1975, 96: 922–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Gwatkin RB, Andersen OF. Hamster oocyte maturation in vitro: Inhibition by follicular components. Life Sci 1976, 19: 527–36.PubMedCrossRefGoogle Scholar
  7. 7.
    Hillensjo T, Channing CP, Pomerantz SH, Schwartz-Kripner A. Intrafollicular control of oocyte maturation in the pig. In Vitro 1979, 15: 32–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Dekel N, Beers W. Development of the Ray oocyte in vitro: inhibition and induction of maturation in the presence and absence of the cumulus oophorus. Dev Biol 1980, 75: 247–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Brailly S, Gougeon A, Milgrom E, Bomsel HO, Papiernik E. Androgens and progestins in the human ovarian follicle: differences in the evolution of preovulatory, healthy nonovulatory, and atretic follicles. J Clin Endocrinol Metab 1981, 53: 128–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Filicori M. The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil Steril 1999, 71: 405–14.PubMedCrossRefGoogle Scholar
  11. 11.
    Patsoula E, Loutradis D, Drakakis P, Kallianidis K, Bletsa R, Michalas S. Expression of mRNA for the LH and FSH receptors in mouse oocytes and preimplantation embryos. Reproduction 2001, 121: 455–61.PubMedCrossRefGoogle Scholar
  12. 12.
    Robert C, Gagne D, Lussier JG, Bousquet D, Barnes FL, Sirard MA. Presence of LH receptor mRNA in granulosa cells as a potential marker of oocyte developmental competence and characterization of the bovine splicing isoforms. Reproduction 2003, 125: 437–46.PubMedCrossRefGoogle Scholar
  13. 13.
    Minegishi T, Tano M, Abe Y, Nakamura K, Ibuki Y, Miyamoto K. Expression of luteinizing hormone/human chorionic gonadotrophin (LH/HCG) receptor mRNA in the human ovary. Mol Hum Reprod 1997, 3: 101–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Okamura H, Katabuchi H, Ohba T. What we have learned from isolated cells from human ovary? Mol Cell Endocrinol 2003, 202: 37–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Ross GT. Gonadotropins and preantral follicular maturation in women. Fertil Steril 1974, 25: 522–43.PubMedGoogle Scholar
  16. 16.
    Billig H, Furuta I, Hsueh A. Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. Endocrinology 1993, 133: 2204–12.PubMedGoogle Scholar
  17. 17.
    Andersen CY. Characteristics of human follicular fluid associated with successful conception after in vitro fertilization. J Clin Endocrinol Metab 1993, 77: 1227–34.PubMedGoogle Scholar
  18. 18.
    Filicori M, Flamigni C, Cognigni GE, et al. Different gonadotropin and leuprorelin ovulation induction regimens markedly affect follicular fluid hormone levels and folliculogenesis. Fertil Steril 1996, 65: 387–93.PubMedGoogle Scholar
  19. 19.
    Weil SJ, Vendola K, Zhou J, et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1998, 83: 2479–85.PubMedCrossRefGoogle Scholar
  20. 20.
    Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999, 84: 2951–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Botero-Ruiz W, Laufer N, DeCherney AH, Polan ML, Haseltine FP, Behrman HR. The relationship between follicular fluid steroid concentration and successful fertilization of human oocyte in vitro. Fertil Steril 1984, 41: 820–6.PubMedGoogle Scholar
  22. 22.
    Kreiner D, Liu HC, Itskovitz J, Veeck L, Rosenwaks Z. Follicular fluid estradiol and progesterone are markers of preovulatory oocyte quality. Fertil Steril 1987, 48: 991–4.PubMedGoogle Scholar
  23. 23.
    Rabinovici J, Blankstein J, Goldman B, et al. In vitro fertilization and primary embryonic cleavage are possible in 17 alpha-hydroxylase deficiency despite extremely low intrafollicular 17 beta-estradiol. J Clin Endocrinol Metab 1989, 68: 693–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Pellicer A, Miro F, Sampaio M, Gomez E, Bonila-Musoles FM. In vitro fertilization as a diagnostic and therapeutic tool in a patient with partial 17,20-desmolase deficiency. Fertil Steril 1991, 55: 970–5.PubMedGoogle Scholar
  25. 25.
    Filicori M, Cognigni G, Pocognoli P, Ciampaglia W, Bernardi S. Current concepts and novel applications of LH activity in ovarian stimulation. Trends Endocrinol Metab 2003, 14: 267–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Jones HW. What has happened? Where are we? Hum Reprod 1996, 11: 943–9.CrossRefGoogle Scholar
  27. 27.
    Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 2003, 14: 236–42.PubMedCrossRefGoogle Scholar
  28. 28.
    Fauser BC, de Jong D, Olivennes F et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonists after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002, 87: 709–15.PubMedCrossRefGoogle Scholar
  29. 29.
    Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical evidence for an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003, 18: 314–22.PubMedCrossRefGoogle Scholar
  30. 30.
    The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998, 83: 1507–14.Google Scholar
  31. 31.
    Filicori M, Cognigni GE, Taraborrelli S et al. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J Clin Endocrinol Metab 1999, 84: 2659–63.PubMedGoogle Scholar
  32. 32.
    Filicori M, Cognigni GE, Taraborrelli S et al. Lutenizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab 2001, 86: 337–43.PubMedCrossRefGoogle Scholar
  33. 33.
    Westergaard LC, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000, 15: 1003–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Fleming R, Rehka P, Jamieson ME, et al. Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum Reprod 2000, 15: 1440–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Fleming R, Lloyd F, Herbert, et al. Effect of profound suppression of LH during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified FSH. Hum Reprod 1998, 13: 1788–92.PubMedCrossRefGoogle Scholar
  36. 36.
    Balasch J, Vidal E, Penarrubia J, et al. Suppression of LH during ovarian stimulation: analyzing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Hum Reprod 2001, 16: 1636–43.PubMedCrossRefGoogle Scholar
  37. 37.
    Hillier SG. Current concepts of the role of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994, 9: 188–91.PubMedGoogle Scholar
  38. 38.
    de Jong D, Macklon NS, Eijkemans MJ, et al. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). Fertil Steril 2001, 75: 688–93.PubMedCrossRefGoogle Scholar
  39. 39.
    Filicori M, Cognigni GE, Samara A, et al. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update 2002, 8: 543–57.PubMedCrossRefGoogle Scholar
  40. 40.
    Filicori M, Cognigni GE, Taraborrelli S, Parmegiani L, Bernardi S, Ciampaglia W. Intracytoplasmic sperm injection pregnancy after low-dose human chorionic gonadotropin alone to support ovarian folliculogenesis. Fertil Steril 2002, 78: 414–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Filicori M, Cognigni GE, Pocognoli P, et al. Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration. Hum Reprod 2002, 17: 2009–15.PubMedCrossRefGoogle Scholar
  42. 42.
    Balasch J, Creus M, Fabregues F, et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction. J Assist Reprod Genet 2001, 18: 250–6.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Daya S, Gumby J, Hughes EG, Collins JA, Sagle MA. Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization. Hum Reprod 1995, 10: 392–6.CrossRefGoogle Scholar
  44. 44.
    Balasch J, Miro F, Burzaco I, et al. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod 1995, 10: 1678–83.PubMedGoogle Scholar
  45. 45.
    Schoot DC, Harlin J, Shoham Z, et al. Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women. Hum Reprod 1994, 9: 1237–42.PubMedGoogle Scholar
  46. 46.
    Burgues S. The Spanish Collaborative Group on female hypogonadotrophic hypogonadism. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain. Hum Reprod 2001, 16: 2525–32.PubMedCrossRefGoogle Scholar
  47. 47.
    Doody KM, Nackley AC, Kevin J. Doody. Daily low dose recombinant hCG and low dose recombinant FSH: a novel treatment for hypogonadotrophic hypogonadism. Fertil Steril 2002, 78 (Suppl. 1): S105.CrossRefGoogle Scholar
  48. 48.
    Filicori M, Bonizzato A, Pradel U, Foresta C, LaSala GB, Mastella G. Low-dose human chorionic gonadotrophin therapy can improve sensitivity to exogenous folliclestimulating hormone in patients with secondary amenorrhea. Fertil Steril 1999, 72: 1118–20.PubMedCrossRefGoogle Scholar
  49. 49.
    The ganirelix dose-finding study group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998, 13: 3023–31.CrossRefGoogle Scholar
  50. 50.
    Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropinreleasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992, 58: 888–96.PubMedGoogle Scholar
  51. 51.
    Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormonereleasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000, 15: 526–31.PubMedCrossRefGoogle Scholar
  52. 52.
    van der Meer M, Hompes PG, Scheele F, Schoute E, Popp-Snijders C, Schoemaker J. The importance of endogenous feedback for monofollicular growth in low-dose step-up ovulation induction with follicle-stimulating hormone in polycystic ovary syndrome: a randomized study. Fertil Steril 1996, 66: 571–6.PubMedGoogle Scholar
  53. 53.
    Filicori M, Cognigni GE, Taraborrelli S, Parmegiani L, Bernardi S, Ciampaglia W. Intracytoplasmic sperm injection pregnancy after low-dose human chorionic gonadotropin alone to support ovarian folliculogenesis. Fertil Steril 2002, 78: 414–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Filicori M, Cognigni GE, Tabarelli C, et al. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 2002, 87: 1156–61.PubMedCrossRefGoogle Scholar
  55. 55.
    Fawzy M, Harrison RF, Knight PG, et al. The effect of gonadotrophins with differing LH/FSH ratios on the secretion of the various species of inhibin in women receiving IVF. Hum Reprod 2001, 16: 1092–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Sills ES, Levy DP, Moomjy M, McGee M, Rosenwaks Z. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Hum Reprod 1999, 14: 2230–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Devroey P, Mannaerts B, Smitz J, Coelingh Bennink H, Van Steirteghem A. Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens. Hum Reprod 1994, 9: 1064–9.PubMedGoogle Scholar
  58. 58.
    Ku SY, Suh CS, Kim SH, Choi YM, Kim JG, Moon SY. A pilot study of the use of low dose human menopausal gonadotropin in ovulation induction. Eur J Obstet Gynecol Reprod Biol 2003, 109: 55–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe G, Picconeri MG. Use of recombinant follicle-stimulating hormone (Gonal F) and recombinant luteinizing hormone (Luveris) for multiple follicular stimulation in patients with a suboptimal response to in vitro fertilization. Fertil Steril 2003, 79: 1037–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Beckers NG, Macklon NS, Eijkemans MJ, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003, 88: 4186–92.PubMedCrossRefGoogle Scholar
  61. 61.
    Thompson KA, LaPolt PS, Rivier J, Henderson G, Dahl KD, Meldrum DR. Gonadotropin requirements of the developing follicle. Fertil Steril 1995, 63: 273–6.PubMedGoogle Scholar
  62. 62.
    Shapiro DB. GnRH antagonists in normal-responder patients. Fertil Steril 2003, 80: 8–15.CrossRefGoogle Scholar
  63. 63.
    Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Initiation of gonadotropinreleasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab 2003, 88: 5632–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Ikeda M, Taga M, Kurogi K, Minaguchi H. Gene expression of gonadotrophin-releasing hormone, but not its receptor, in human endometrium and decidua. Mol Endocrinol 1997, 135: 165–8.CrossRefGoogle Scholar
  65. 65.
    Brus L, Lambalk CB, de Koning J. Specific gonadotrophinreleasing hormone analog binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Hum Reprod 1997, 12: 769–73.PubMedCrossRefGoogle Scholar
  66. 66.
    Anderson RE, Cragun JM, Chang RJ, Stanczyk FZ, Lobo RA. A pharmacodynamic comparison of human urinary follicle-stimulating hormone and human menopausal gonadotropin in normal women and polycystic ovary syndrome. Fertil Steril 1989, 52: 216–20.PubMedGoogle Scholar
  67. 67.
    Sagle MA, Hamilton-Fairley D, Kiddy DS, Franks S. A comparative, randomized study of low-dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome. Fertil Steril 1991, 55: 56–60.PubMedGoogle Scholar
  68. 68.
    Shoham Z, Jacobs HS, Insler V. Luteinizing hormone: its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase. Fertil Steril 1993, 59: 1153–61.PubMedGoogle Scholar
  69. 69.
    Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2000: CD000410.Google Scholar
  70. 70.
    Hughes E, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev 2000: CD000087.Google Scholar
  71. 71.
    RS Rittmaster. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide. J Clin Endocrinol Metab 1988, 67: 651–5.PubMedCrossRefGoogle Scholar
  72. 72.
    Elkind-Hirsch KE, Webster BW, Brown CP, Vernon MW. Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome. Fertil Steril 2003, 79: 603–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Cheung AP, Pride SM, Yuen BH, Sy L. In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome. Hum Reprod 2002, 17: 2540–7.PubMedCrossRefGoogle Scholar
  74. 74.
    Shoham Z, Schacter M, Loumaye E, Weissman A, Mac-Namee M, Insler V. The luteinizing hormone surge-the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil Steril 1995, 64: 237–51.PubMedGoogle Scholar
  75. 75.
    le Cotonnec JY, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertil Steril 1998, 69: 189–94.PubMedCrossRefGoogle Scholar
  76. 76.
    Manau D, Fabregues F, Arroyo V, Jimenez W, Vanrell JA, Balasch J. Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization. Fertil Steril 2002, 78: 1261–7.PubMedCrossRefGoogle Scholar
  77. 77.
    The European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001, 86: 2607–18.CrossRefGoogle Scholar
  78. 78.
    Balasch J, Fabregues F. Is luteinizing hormone needed for optimal ovulation induction? Curr Opin Obst Gynecol 2002, 14: 265–74.CrossRefGoogle Scholar
  79. 79.
    Filicori M. Use of luteinizing hormone in the treatment of infertility: time for reassessment? Fertil Steril 2003, 79: 253–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Tesarik J, Mendoza C. Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Hum Reprod 2002, 17: 3129–37.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2005

Authors and Affiliations

  1. 1.Endocrine Department“Hippokrateion” Hospital of AthensAthensGreece

Personalised recommendations